Filing excerpt
Capital expenditures for fixed assets for the nine months ended March 31, 2026 and 2025 were $20.4 million and $26.1 million, respectively.
sec.gov/Archives/edgar/data/842023/000110465926056302/tech-20260331x1...Read the full source
Bio-Techne10-Q: Capacity constraint
Company investing ~$27M in FY2026 CapEx to address production capacity constraints.
What happened
Bio-Techne has spent $20.4M and plans to spend another $7M in fiscal 2026 on capital expenditures specifically to increase production capacity.
Source
Other signals in this filing (4)
- Acquisition announcedBio-Techne forecasts ~$1B payment to acquire remaining 80.1% of Wilson WolfAcquisition announced
- Debt refinancingBio-Techne forecasts ~$1B payment to complete Wilson Wolf acquisition between fiscal 2026-2028.Debt refinancing
- Capex increaseBio-Techne plans $7M in capital expenditures for remainder of fiscal 2026 to increase capacity.Capex increase
- Market expansionBio-Techne investing ~$27M in FY2026 capital expenditures for capacity expansionMarket expansion
Extracted by Autobound
From the Signal API record- Signal
- 10-Q: Capacity constraint
What this signalsFilings often name leadership changes, deals and spending plans.
- Filed
- May 6, 2026
More from Bio-Techne
- PatentsBio-Techne Corporation's patent output is steady: 1 grant in the past year, 0 in the past 30 days.Patents
- 8-KBio-Techne shareholders approve acquisition by Merck KGaA, Darmstadt, Germany8-K
- New locationBio-Techne Opens New Customer Experience Centre in Düsseldorf, Strengthening Scientific Exchange and Collaboration with Customers in EuropeNew location
- CertificationBio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate GoalsCertification
- 10-KBio-Techne completed acquisition of spatial biology firm Lunaphore in fiscal 202410-K
- GlassdoorEmployees report lack of growth opportunities and encouragementGlassdoor
More 10-Q signals at other companies
- SEC 10-QMillerKnoll, Inc.Jeffrey M. Stutz appointed Interim Chief Executive Officer.SEC 10-Q
- SEC 10-QCID HoldCo, Inc.Disclosed material weaknesses in financial reporting due to insufficient accounting staff and controls.SEC 10-Q
- SEC 10-QScholastic CorporationCore school channels decline with fewer book fairs and lower club participation.SEC 10-Q
The full record
From the Signal API recordNumbers
- Dollar figure
- $27.4M (Total expected capital expenditures for fiscal 2026 ($20.4M spent + $7M planned).)
Details
- CIK
- 842023
- Accession number
- 0001104659-26-056302
- Timeframe
- Current year
- Filing year
- 2026
- Fiscal year
- 0
- Why it matters
- Scaling solutions needed
- Signal category
- Operations
Extraction
- Confidence
- High
- Relevance
- 80%
- Sentiment
- Positive
- Detected
- May 12, 2026
- signal_type
sec-10q- signal_subtype
capacityConstraint
Use this data
Get every 10-Q signal for Bio-Techne and the companies you sell to, in the tools you already use.
Ask Claude about it
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Bio-Techne this week?”
Send it to your own tools
The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.
Try it free
Sign up and spend your free credits on the companies you sell to.
Start Free1,000 free credits
The API returns more than this page shows
This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the API
Signal
signal_nameValue in the APIassociationValue in the API
Start Free1,000 free creditsUse it in Claude via MCP
Show the full JSONHide the full JSONThe record on this page and the API request
GET /v1/signals/f5cc9c02-e02a-4da0-936b-5d52a17e603d returns this record as JSON. POST /v1/companies/enrich returns every signal for bio-techne.com.
{
"signal_id": "f5cc9c02-e02a-4da0-936b-5d52a17e603d",
"signal_type": "sec-10q",
"signal_subtype": "capacityConstraint",
"detected_at": "2026-05-12T09:24:55.495+00:00",
"company": {
"name": "Bio-Techne",
"domain": "bio-techne.com"
},
"data": {
"detail": "Bio-Techne has spent $20.4M and plans to spend another $7M in fiscal 2026 on capital expenditures specifically to increase production capacity. This indicates they are facing or anticipating demand outstripping their manufacturing capabilities, creating an opportunity for solutions that improve throughput and efficiency.",
"metrics": {
"timeframe": "current_year",
"dollar_context": "Total expected capital expenditures for fiscal 2026 ($20.4M spent + $7M planned).",
"dollar_millions": 27.4
},
"summary": "Company investing ~$27M in FY2026 CapEx to address production capacity constraints.",
"excerpts": "Capital expenditures for fixed assets for the nine months ended March 31, 2026 and 2025 were $20.4 million and $26.1 million, respectively.",
"relevance": 0.8,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/842023/000110465926056302/tech-20260331x10q.htm",
"filing_date": "2026-05-06",
"filing_year": 2026,
"fiscal_year": 0,
"sales_relevance": "Scaling solutions needed",
"signal_category": "operations"
}
}
curl https://signals.autobound.ai/v1/signals/f5cc9c02-e02a-4da0-936b-5d52a17e603d \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"bio-techne.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.